Brittany Craiglow, MD, reviews the TRuE-AD3 trial, a phase 3, randomized double-blind study (NCT04921969) that assessed the safety and efficacy of ruxolitinib in treating pediatric patients with atopic dermatitis. This treatment showed long-term safety and disease control by Week 8 in children aged 2 to 11 years. She also discusses the importance of providing a therapy that has a limited adverse event profile which provides families encouragement when deciding on a treatment for their young children.
Topics covered:
- Long-term treatment in pediatric patients with atopic dermatitis
- Relevance of safety data for young children
- The phase 3, randomized, double-blind TRuE-AD3 study
Related resources:
Lawrence Eichenfield, MD: Insights from the TRuE-AD3 Pediatric Atopic Dermatitis Trial
Lisa Swanson, MD: Pediatric Dermatology Without Limits
